share_log

Burcon Reports Fiscal 2024 First Quarter Results

Burcon Reports Fiscal 2024 First Quarter Results

Burcon 公佈了 2024 財年第一季度業績
newsfile ·  2023/08/15 04:07

Vancouver, British Columbia--(Newsfile Corp. - August 14, 2023) - Burcon NutraScience Corporation (TSX: BU) ("Burcon" or the "Company"), a global technology leader in the development of plant-based proteins for foods and beverages, reported results for the fiscal first quarter ended June 30, 2023.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2023年8月14日)——食品和飲料植物性蛋白開發領域的全球技術領導者Burcon NutraScience Corporation(多倫多證券交易所股票代碼:BU)(“Burcon” 或 “公司”)公佈了截至2023年6月30日的第一財季業績。

Operational highlights for the first quarter ended June 30, 2023:

截至2023年6月30日的第一季度運營亮點:

During the quarter, Burcon:

在本季度中,Burcon:

  • closed a fully subscribed $3.4 million non-brokered private placement;
  • announced that its sunflower protein process is commercially ready;
  • launched its Winnipeg Technical Centre as a pilot plant processing and scale-up validation service provider;
  • expanded its scope of strategic partnership opportunities for each of its innovative plant-based protein technologies; and
  • advanced the due diligence process to commercialize its hempseed protein technology
  • 完成了340萬美元全額認購的非經紀私募配售;
  • 宣佈其向日葵蛋白工藝已準備就緒;
  • 作爲試點工廠加工和放大驗證服務提供商,啓動了其溫尼伯技術中心;
  • 擴大了其每種創新的植物性蛋白質技術的戰略合作機會範圍;以及
  • 推進了盡職調查流程,將其大麻籽蛋白技術商業化

Subsequent to the quarter-end, Burcon:

四分之一結束後,Burcon:

  • partnered with HPS Food and Ingredients Inc. to launch the world's first soluble hempseed protein isolate; and
  • successfully launched its soluble hempseed protein isolate at IFT FIRST 2023 in Chicago, IL
  • 與 HPS Food and Inc.合作推出了世界上第一種可溶性大麻籽蛋白分離物;以及
  • 在伊利諾伊州芝加哥舉行的 IFT FIRST 2023 上成功推出其可溶性大麻籽蛋白分離物

Management Commentary

管理層評論

Burcon began fiscal 2024 by strengthening its balance sheet with a $3.4 million non-brokered private placement, which, together with its recent cost-cutting measures and pursuit of potential government funding, is expected to provide us with sufficient runway to execute our Burcon 2.0 strategy. Continued support from our long-term shareholders allowed us to raise funds well above our initial target in the May 2023 private placement. Our focus going forward is to create value for the Company and in particular, for our shareholders who believe in our vision and strategy.

在2024財年初,Burcon通過340萬美元的非經紀私募加強了資產負債表,再加上其最近的削減成本的措施和對潛在政府資金的追求,預計將爲我們提供足夠的跑道來執行我們的Burcon 2.0戰略。長期股東的持續支持使我們能夠在2023年5月的私募中籌集的資金遠高於我們最初的目標。我們未來的重點是爲公司,特別是爲相信我們願景和戰略的股東創造價值。

Our revised Burcon 2.0 strategy, which includes identifying additional revenue sources, getting closer to customers and gaining more influence over the production of our proteins, is a path for us to create value for the Company. Our partnership with HPS Food and Ingredients Inc. ("HPS") is the first of many proof points for Burcon 2.0. The partnership is an excellent marriage of expertise, creating positive synergistic results. Burcon has production and process engineering expertise, while HPS has access to hempseed farmers and a global network of hemp ingredient customers. In addition, we continue to evaluate different routes to market for each of our protein technologies, including the potential use of assets from Merit Functional Foods. We are thrilled about our partnership with HPS and are equally excited about additional opportunities we are pursuing to monetize our IP.

我們修訂後的Burcon 2.0戰略包括尋找額外的收入來源,拉近與客戶的距離,以及對蛋白質生產獲得更大的影響力,是我們爲公司創造價值的途徑。我們與HPS Food and Ingredients Inc.(“HPS”)的合作伙伴關係是Burcon 2.0衆多證據中的第一個。這種夥伴關係是專業知識的完美結合,創造了積極的協同效應。Burcon 擁有生產和工藝工程專業知識,而 HPS 可以接觸到大麻籽種植者和全球大麻原料客戶網絡。此外,我們將繼續評估每種蛋白質技術的不同上市途徑,包括Merit Fuctional Foods資產的潛在用途。我們對與HPS的合作感到非常興奮,也同樣對我們尋求通過知識產權獲利的更多機會感到興奮。

Subsequent to quarter-end, HPS and Burcon successfully launched our hempseed protein isolate at the world's largest food ingredient tradeshow - Institute of Food Technologists 2023 Annual Meeting and Exposition ("IFT FIRST") - in Chicago, IL. Our hempseed protein isolate with 95% protein content received overwhelming positive feedback from customers and industry peers. Based on the positive feedback received, we anticipate moving forward on our commercial plans to quickly bring this best-in-class hempseed protein ingredient to market and further validate our Burcon 2.0 strategy.

季度末之後,HPS和Burcon在伊利諾伊州芝加哥舉行的世界上最大的食品原料貿易展——食品技術專家協會2023年年會和博覽會(“IFT FIRST”)上成功推出了我們的大麻籽分離蛋白。我們的大麻籽分離蛋白質含量爲 95%,收到了客戶和行業同行的壓倒性積極反饋。根據收到的積極反饋,我們預計我們的商業計劃將向前推進,以迅速將這種一流的大麻籽蛋白成分推向市場,並進一步驗證我們的Burcon 2.0戰略。

During the quarter, we successfully completed end-to-end validation trials of our novel sunflower protein process, a major milestone in the commercialization roadmap. We see tremendous potential in our unique sunflower protein to disrupt the plant-based ingredient market. We believe that reaching this milestone brings us one step closer to commercialization. Our discussions with potential partners continue to progress as we complete further due diligence while exploring additional paths to market.

在本季度,我們成功完成了對我們新型向日葵蛋白工藝的端到端驗證試驗,這是商業化路線圖中的一個重要里程碑。我們看到了我們獨特的向日葵蛋白在顛覆植物性原料市場的巨大潛力。我們相信,達到這一里程碑將使我們離商業化更近一步。隨着我們完成進一步的盡職調查,同時探索其他市場渠道,我們與潛在合作伙伴的討論繼續取得進展。

In addition to commercializing Burcon's proteins, we continue to execute initiatives that focus on our three key strategic themes. Burcon announced that it is offering its pilot plant processing and validation capabilities as a service. By leveraging Burcon's expertise and infrastructure, we can better connect with our customers and industry peers. Burcon's capabilities at its Winnipeg Technical Centre are unique in North America and can provide exceptional value to the growing food ecosystem.

除了將Burcon的蛋白質商業化外,我們還繼續執行以我們的三個關鍵戰略主題爲重點的舉措。Burcon 宣佈,它將以服務形式提供其中試工廠處理和驗證能力。通過利用 Burcon 的專業知識和基礎架構,我們可以更好地與客戶和行業同行建立聯繫。Burcon在溫尼伯技術中心的能力在北美是獨一無二的,可以爲不斷增長的食物生態系統提供非凡的價值。

Going forward, we see a potential path to revenues with our hempseed protein isolate and is a priority for Burcon to work closely with our partners and customers to ensure we bring forth a commercial-scale, high-quality hempseed protein product that meets the evolving preferences of customers worldwide.

展望未來,我們看到了大麻籽分離蛋白的潛在收入途徑,Burcon的首要任務是與合作伙伴和客戶密切合作,確保我們推出符合全球客戶不斷變化的偏好的商業規模、高質量的大麻籽蛋白產品。

Financial Results (in Canadian dollars)

財務業績 (以加元計)

Net loss totaled $1.9 million or $0.02 per basic and diluted share for the current quarter, as compared to $4.0 million or $0.04 per basic and diluted share in same period last year. The lower loss this quarter, as compared to the same year-ago quarter, is due almost entirely to the share of loss in Merit recorded during the first quarter of fiscal 2023. The Company's cash conservation efforts have also contributed to lower expenditures.

本季度淨虧損總額爲190萬美元,合每股基本和攤薄後每股虧損0.02美元,而去年同期爲400萬美元,基本和攤薄後每股虧損0.04美元。與去年同期相比,本季度的虧損較低,幾乎完全是由於2023財年第一季度錄得的Merit虧損份額。該公司的現金節約努力也有助於降低支出。

Research and development expenses totalled $936,000, as compared to $1,248,000 in the same year-ago quarter. The decrease of $312,000 is due mainly to lower intellectual property expenses, driven by optimization of the patent portfolio that resulted in lower maintenance fees.

研發費用總額爲93.6萬美元,而去年同期爲124.8萬美元。減少31.2萬美元主要是由於專利組合的優化導致維護費用降低,知識產權支出減少。

General and administrative expenses totalled $837,000, as compared to $911,000 in the same year-ago quarter. The decrease of $74,000 is due mainly to the Nasdaq annual fee and U.S. investor relations consulting expenses incurred during the first quarter of last year.

一般和管理費用總額爲83.7萬美元,而去年同期爲91.1萬美元。減少74,000美元,主要是由於納斯達克的年費和去年第一季度產生的美國投資者關係諮詢費用。

During the quarter, Burcon completed a private placement for net proceeds of $3.4 million. At June 30, 2023, cash balances totaled $3.6 million compared to $1.5 million at March 31, 2023. Subsequent to the quarter-end, Burcon's largest shareholder, Large Scale Investments, agreed to extend the maturity date of the first tranche of the secured loan from July 1, 2024 to July 1, 2025. Burcon expects its current cash resources to fund its operations to February 2024, and further to February 2025, if conditions for advance under the second tranche are satisfied. These dates may potentially be extended if the Company receives funding or generates revenues from other sources including, not limited to, government assistance, pilot plant processing and scale-up validation services.

在本季度,Burcon完成了私募配售,淨收益爲340萬美元。截至2023年6月30日,現金餘額總額爲360萬美元,而截至2023年3月31日爲150萬美元。季度末之後,Burcon的最大股東Large Scale Investments同意將第一批擔保貸款的到期日從2024年7月1日延長至2025年7月1日。Burcon預計,如果第二批預付款條件得到滿足,其目前的現金資源將爲其運營提供資金至2024年2月,再到2025年2月。如果公司從其他來源獲得資金或產生收入,包括但不限於政府援助、試點工廠加工和擴大規模驗證服務,則這些日期可能會延長。

Conference Call Details

電話會議詳情

Burcon will hold an investor conference call and webcast on Monday, August 14, 2023 at 5:00pm ET.

Burcon將於美國東部時間2023年8月14日星期一下午5點舉行投資者電話會議和網絡直播。

A link to the webcast of the conference call is available on Burcon's website under "Presentations" or directly here. The webcast will also be archived for future playback.

電話會議網絡直播的鏈接可在Burcon網站上的 “演示文稿” 下找到,也可以直接點擊這裏。網絡直播也將存檔以備將來播放。

Investors interested in participating in the live call can dial in using the details below:

有興趣參加現場電話會議的投資者可以使用以下詳細信息進行撥號:

Date: Monday August 14, 2023

日期:2023 年 8 月 14 日星期一

Time: 5:00 p.m. Eastern time (2:00 p.m. Pacific time)

時間:美國東部時間下午 5:00(太平洋時間下午 2:00)

Toll-free dial-in (North America): 1-855-327-6837

免費撥號(北美):1-855-327-6837

Dial-in (toll/international): 1-631-891-4304

撥入(電話/國際):1-631-891-4304

Conference ID: 10022225

會議編號:10022225

About Burcon NutraScience Corporation

關於 Burcon NutraScience 公司

Burcon is a global technology leader in the development of plant-based proteins for foods and beverages. Our proteins exhibit superior functionality, taste and nutrition, making them ideal ingredients for food formulators. With over two decades of experience, Burcon has amassed an extensive patent portfolio covering its specialty plant-based proteins derived from pea, canola, soy, hemp and sunflower seeds, among other plant sources. Burcon is striving to become a vertically integrated provider of specialty plant-based protein solutions that deliver on health, nutrition and sustainability. Supporting the growing trend towards a plant-based diet, Burcon is developing premium protein ingredients that we believe are better for you and better for the planet. For more information, visit burcon.ca.

Burcon 是開發用於食品和飲料的植物性蛋白質的全球技術領導者。我們的蛋白質具有卓越的功能、口感和營養,是食品配方設計師的理想原料。憑藉二十多年的經驗,Burcon積累了廣泛的專利組合,涵蓋了其源自豌豆、油菜籽、大豆、大麻和葵花籽等植物來源的特種植物性蛋白質。Burcon 正在努力成爲一家垂直整合的專業植物性蛋白質解決方案提供商,提供健康、營養和可持續發展。爲了支持植物性飲食的增長趨勢,Burcon正在開發優質的蛋白質成分,我們認爲這些成分對您有益,對地球也有好處。欲了解更多信息,請訪問 burcon.ca。

Forward-Looking Information Cautionary Statement

前瞻性信息警示聲明

The TSX has not reviewed and does not accept responsibility for the adequacy of the content of the information contained herein. This press release contains forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and applicable Canadian securities legislation, including our ability to successfully commercialize our hemp protein isolate and to validate and execute our Burcon 2.0 strategy. Forward-looking statements or forward-looking information involve risks, uncertainties and other factors that could cause actual results, performances, prospects and opportunities to differ materially from those expressed or implied by such forward-looking statements. Forward-looking statements or forward-looking information can be identified by words such as "anticipate," "aim", "intend," "plan," "goal," "project," "estimate," "expect," "believe," "future," "likely," "may," "should," "could," "will" and similar references to future periods. All statements included in this release, other than statements of historical fact, are forward-looking statements. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements or information. Important factors that could cause actual results to differ materially from Burcon's plans and expectations include the implementation of our business model and growth strategies; trends and competition in our industry our future business development, financial condition and results of operations and our ability to obtain financing cost-effectively; potential changes of government regulations; and other risks and factors detailed herein and from time to time in the filings made by Burcon with securities regulators and stock exchanges, including in the section entitled "Risk Factors" in Burcon's annual information form for the year ended March 31, 2023 and its other public filings with Canadian securities regulators on SEDAR at . This list is not exhaustive of the factors that may affect any of the Company's forward-looking statements or information. Any forward-looking statement or information speaks only as of the date on which it was made, and, except as may be required by applicable securities laws, Burcon disclaims any intent or obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise. Although Burcon believes the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance, and, accordingly, investors should not rely on such statements.

多倫多證券交易所尚未對其中包含的信息內容的充分性進行審查,也不承擔任何責任。本新聞稿包含1995年《美國私人證券訴訟改革法》和適用的加拿大證券立法所指的前瞻性陳述或前瞻性信息,包括我們成功將大麻蛋白分離物商業化以及驗證和執行我們的Burcon 2.0戰略的能力。前瞻性陳述或前瞻性信息涉及風險、不確定性和其他因素,這些因素可能導致實際業績、業績、前景和機會與此類前瞻性陳述所表達或暗示的結果存在重大差異。前瞻性陳述或前瞻性信息可以用 “預期”、“目標”、“打算”、“計劃”、“目標”、“項目”、“估計”、“期望”、“相信”、“未來”、“可能”、“應該”、“可能”、“將” 等詞語來識別,以及對未來時期的類似提法。除歷史事實陳述外,本新聞稿中包含的所有陳述均爲前瞻性陳述。無法保證此類陳述會被證明是準確的,實際結果和未來事件可能與此類陳述或信息中的預期存在重大差異。可能導致實際業績與Burcon的計劃和預期存在重大差異的重要因素包括我們的商業模式和增長戰略的實施;我們行業的趨勢和競爭;未來的業務發展、財務狀況和經營業績以及我們經濟高效地獲得融資的能力;政府監管的潛在變化;以及此處以及Burcon向證券監管機構和證券交易所提交的文件中不時詳述的其他風險和因素,包括本節Burcon截至2023年3月31日止年度的年度信息表及其向加拿大證券監管機構提交的有關SEDAR的其他公開文件中標題爲 “風險因素”,網址爲。此清單並未詳盡列出可能影響公司任何前瞻性陳述或信息的因素。任何前瞻性陳述或信息僅代表其發表之日,而且,除非適用的證券法另有要求,否則伯康不打算或有義務更新任何前瞻性陳述,無論是由於新信息、未來事件還是其他原因。儘管伯康認爲前瞻性陳述中固有的假設是合理的,但前瞻性陳述並不能保證未來的表現,因此,投資者不應依賴此類陳述。

Industry and Investor Contact

行業和投資者聯繫人

Paul Lam
Director, Investor Relations
Burcon NutraScience Corporation
Tel (604) 733-0896, Toll-free (888) 408-7960
plam@burcon.ca

保羅·林
投資者關係總監
Burcon NutraScience 公司
電話 (604) 733-0896,免費電話 (888) 408-7960
plam@burcon.ca

Media Contact:
Steve Campbell, APR
President
Campbell & Company Public Relations
Tel (604) 888-5267
TECH@CCOM-PR.COM

媒體聯繫人:
史蒂夫坎貝爾,APR
主席
坎貝爾公司公共關係
電話 (604) 888-5267
TECH@CCOM-PR.COM

Burcon NutraScience Corporation
Condensed Consolidated Interim Statements of Financial Position
(Unaudited)
As at June 30, 2023 and March 31, 2023
(In Canadian dollars)
June 30, March 31,
2023 2023
Assets
Current assets
Cash 3,571,886 1,456,845
Amounts receivable 169,280 332,118
Prepaid expenses 126,266 75,902
3,867,432 1,864,865
Property and equipment 945,312 983,924
Deferred development costs 5,690,275 5,795,650
Goodwill 1,254,930 1,254,930
11,757,949 9,899,369
Liabilities
Current liabilities
Accounts payable and accrued liabilities 675,720 590,936
Lease liabilities 48,049 34,431
723,769 625,367
Secured loan 5,224,613 5,112,381
Lease liabilities 7,059 24,310
5,955,441 5,762,058
Shareholders' Equity
Capital stock 117,718,241 114,566,577
Contributed surplus 16,830,753 16,763,830
Options 7,381,835 7,279,559
Warrants 228,572 -
Restricted share units 155,496 127,651
Deficit (136,512,389) (134,600,306)
5,802,508 4,137,311
11,757,949 9,899,369
Burcon NutraScience 公司
簡明合併中期財務狀況表
(未經審計)
截至2023年6月30日和2023年3月31日
(以加元計)
6月30日 3月31日
2023 2023
資產
流動資產
現金 3,571,886 1,456,845
應收款項 169,280 332,118
預付費用 126,266 75,902
3,867,432 1,864,865
財產和設備 945,312 983,924
遞延開發成本 5,690,275 5,795,650
善意 1,254,930 1,254,930
11,757,949 9,899,369
負債
流動負債
應付賬款和應計負債 675,720 590,936
租賃負債 48,049 34,431
723,769 625,367
抵押貸款 5,224,613 5,112,381
租賃負債 7,059 24,310
5,955,441 5,762,058
股東權益
資本存量 117718,241 114,566,577
貢獻盈餘 16,830,753 16,763,830
選項 7,381,835 7,279,559
認股證 228,572 -
限制性股票單位 155,496 127,651
赤字 (136,512,389) (134,600,306)
5,802,508 4,137,311
11,757,949 9,899,369
Burcon NutraScience Corporation
Condensed Consolidated Interim Statements of Operations and Comprehensive Loss
(Unaudited)
For the three months ended June 30, 2023 and 2022
(In Canadian dollars)
2023 2022
Revenue
Royalty income - 90,538
Expenses
Research and development 936,370 1,248,277
General and administrative 836,560 911,391
1,772,930 2,159,668
Loss from operations (1,772,930) (2,069,130)
Interest and other income 27,379 116,018
Share of loss in Merit Functional Foods Corporation - (2,003,740)
Interest and other expense (130,974) (40,762)
Foreign exchange (loss) gain (35,558) 1,446
Loss and comprehensive loss for the period (1,912,083) (3,996,168)
Basic and diluted loss per share (0.02) (0.04)
Burcon NutraScience 公司
簡明合併中期經營報表和綜合虧損
(未經審計)
在截至2023年6月30日和2022年6月30日的三個月中
(以加元計)
2023 2022
收入
特許權使用費收入 - 90,538
開支
研究和開發 936,370 1,248,277
一般和行政 836,560 911,391
1,772,930 2,159,668
運營損失 (1,772,930) (2,069,130)
利息和其他收入 27,379 116,018
Merit 功能食品公司的虧損份額 - (2,003,740)
利息和其他費用 (130,974) (40,762)
外匯(虧損)收益 (35,558) 1,446
該期間的虧損和綜合損失 (1,912,083) (3,996,168)
基本和攤薄後每股虧損 (0.02) (0.04)

To view the source version of this press release, please visit

要查看本新聞稿的源版本,請訪問

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論